ERBB2 and breast carcinoma: In this study, we demonstrate that newly synthesized ErbB2 is a direct target of CHIP-mediated ubiquitination and degradation through a post-biosynthetic degradation pathway in the ER and potentially Golgi apparatus, with loss of CHIP expression seen in ErbB2-overexpressing breast cancer cell lines promoting ErbB2 surface expression.